

Form name	No. of respondents	No. of responses/ respondent	Avg. burden/ response (in hrs)
Pediatric Immune Questionnaire .....	100	2	0.5

Dated: August 17, 1999.

**Nancy Cheal,**

*Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-21776 Filed 8-20-99; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

*Name:* Clinical Laboratory Improvement Advisory Committee (CLIAC).

*Times and Dates:* 8:30 a.m.-5 p.m., September 22, 1999. 8:30 a.m.-3:30 p.m., September 23, 1999.

*Place:* CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

*Status:* Open to the public, limited only by the space available. The meeting rooms accommodate approximately 85 people.

*Purpose:* This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

*Matters To Be Discussed:* The agenda will include an update on CLIA implementation; presentations of data and discussion of laboratory workforce issues, including potential shortages of qualified laboratory personnel and the education/skill levels of current personnel.

The Committee solicits oral and written testimony on the laboratory workforce issues of potential shortages of qualified laboratory personnel and the education/skill levels of current personnel. Requests to make an oral presentation should be submitted in writing to the contact person listed below by close of business, September 16, 1999. All requests to make oral comments should contain the name, address, telephone number, and organizational affiliation of the presenter. Written comments should not exceed five single-spaced typed pages in length and

should be received by the contact person listed below by close of business, September 16, 1999.

Agenda items are subject to change as priorities dictate.

*Contact Person for Additional Information:* John C. Ridderhof, Dr.P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, M/S G-25, Atlanta, Georgia 30341-3724, telephone 770/488-8076, FAX 770/488-8282.

The Director, Management and Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 16, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 99-21775 Filed 8-20-99; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Prevalence of STDs and TB Infection in Persons Entering Corrections Facilities.**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

*Name:* Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Prevalence of STDs and TB Infection in Persons Entering Corrections Facilities, Program Announcement #99000-D.

*Time and Date:* 8:30 a.m.-9 a.m., September 2, 1999 (Open); 9 a.m.-4:30 p.m., September 2, 1999 (Closed).

*Place:* National Center for HIV, STD, and TB Prevention, CDC, Corporate Square,

Building 10, Conference Room 1304, Atlanta, Ga. 30329.

*Status:* Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to P.L. 92-463.

*Matters to be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement #99000-D. Due to administrative delays this notice is published less than 15 days prior to the meeting.

*Contact person for more information:* Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639-8025, e-mail eow1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 16, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-21769 Filed 8-18-99; 12:52 pm]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Trends in STD Prevalence, Tuberculosis, and HIV Risk Behaviors Among Men Who Have Sex With Men**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

*Name:* Disease, Disability and Injury Prevention and Control Special Emphasis Panel: Fiscal Year 1999 Competitive Supplemental Funds for Comprehensive STD Prevention Systems: Monitoring Trends in